To understand the clinical meaning of MMR deficiency in breast cancer, we assessed a large breast cancer tissue microarray series linked to detailed biomarker and long-term outcome data for immunohistochemically determined loss of MSH2, MSH6, MLH1 or PMS2. This evidence concerns the gene MLH1 and hyperinsulinemic hypoglycemia, familial, 4.